This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Join Mailing List   |   Jobs   |   Print Page   |   Contact Us   |   Sign In   |   Join
News & Press: Opportunities for Participation

Participate in the New PUP-SWITCH Study

Friday, May 29, 2020   (0 Comments)
Share |

Please participate in the PUP-SWITCH observational cohort study targeting severe hemophilia A patients who have received FVIII replacement therapy. This study aims to make use of pre-existing data in order to evaluate the risk upon switching from the use of plasma-derived FVIII (pdFVIII) concentrates to the use of recombinant FVIII (rFVIII) products, after the period of higher risk for inhibitor occurrence has passed.

A survey has been designed to collect data on patients that have already been treated according to the local standard practice, in agreement with the treatment strategy of PUP-SWITCH.

The surveyors kindly invite participation from all hemophilia treatment centers in which the practice of “initially treating with pdFVIII (for at least 50 and at maximum 75 exposure days) without the patient developing an inhibitor, then switching to rFVIII (standard or extended half-life)” has been performed on previously untreated patients (PUPs) or minimally treated patients (MTPs) under six years old with severe hemophilia A. Data collection consists of patient demographics, hemophilia information prior to FVIII treatment, prophylaxis using pdFVIII, switch to rFVIII, and inhibitor development if occurred.

For more information:

Membership Management Software Powered by YourMembership  ::  Legal